<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47063">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493543</url>
  </required_header>
  <id_info>
    <org_study_id>FMM14</org_study_id>
    <nct_id>NCT02493543</nct_id>
  </id_info>
  <brief_title>Autoantibodies on Spinal Cord Injury</brief_title>
  <official_title>Role of Autoantibodies in Spontaneous Functional Recovery After Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Nacional de Parapléjicos de Toledo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Mutua Madrileña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Nacional de Parapléjicos de Toledo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the autoantibody profiles after spinal cord injury
      and their role in spontaneous functional recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most patients experience variable degrees of functional recovery after spinal cord injury
      (SCI), predominantly in the first months after lesion. In SCI animal models, autoantibodies
      are pathogenic and their titers rise up at the time when spontaneous recovery stops. The aim
      of this study is to determine the autoantibody profiles after SCI and to infer their
      relation with functional recovery. To achieve this, autoantibody profiles will be determined
      from a serum blood sample and functional recovery will be evaluated accordingly to
      standardized scales.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in ASIA scores</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in neurological level of injury</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ASIA impairment scale (AIS)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Spinal cord independence measure (SCIM)</measure>
    <time_frame>Until discharge from the hospital (6-12 months)</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>Spinal cord injury</arm_group_label>
    <description>Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Blood collection from the subject's arm</description>
    <arm_group_label>Spinal cord injury</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute spinal cord injury admitted to the Spanish National Hospital for
        Paraplegics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Traumatic or non-progressive vascular SCI

          -  Less than 45 days after lesion

          -  Any neurological level

          -  Complete and incomplete lesions

          -  If patient has been treated with glucocorticoids, it should have passed at least 7
             days from the end of the treatment

        Exclusion Criteria:

          -  Cauda equina syndrome

          -  Autoimmune disorder

          -  Tumor (even if benign)

          -  Neurodegenerative disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Arevalo-Martin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Nacional de Parapléjicos, SESCAM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Unfallklinik Murnau</name>
      <address>
        <city>Murnau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional de Parapléjicos, SESCAM</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 4, 2015</lastchanged_date>
  <firstreceived_date>July 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Nacional de Parapléjicos de Toledo</investigator_affiliation>
    <investigator_full_name>Dr. Angel Arevalo Martin</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <keyword>autoantibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
